【摘要】目的研究连续性肾脏替代治疗(continuous renal replacement therapy，CRRT)过程中体外循环压力变化及其它因素对体外循环寿命的影响。方法纳入重症监护室使用行Prismaflex 机器治疗的成年患者，总计85 名患者，251 个滤器，共10 322.2h。收集治疗中每分钟体外循环压力数据、治疗参数、实验室数据，分析对体外循环寿命的影响。结果轻度双腔导管出口功能不良事件(access
outflow dysfunction,AOD)尚不影响寿命；中重度AOD 事件在不同抗凝亚组中对寿命影响存在差异：发生中重度AOD 事件明显缩短无抗凝组、枸橼酸组的寿命(t 值分别为3.179，1.949；P 值分别为0.002, 0.054)；而在低肝/肝素组未观测到影响(t=0.630, P=0.950)。通过体外循环寿命的多因素COX 模型分析，提示中重度AOD 事件是其危险因素(β=0.638，HR=1.893，95% CI：1.300～2.756，P=0.001)，枸橼酸(β=- 0.906, HR=0.404, 95% CI：0.304～0.537, P＜0.001) 及CVVHDF(β=- 0.722, HR=0.486，95% CI：0.335～0.704，P＜0.001)是保护因素。结论研究提示使用枸橼酸，CVVHDF 能有效延长体外循环。当使用枸橼酸、无抗凝时，若发生中重度AOD，应通过调整循环入口的功能状态来延长循环寿命而不是一味提高抗凝强度。
【Abstract】Objective To study the effects of continuous extracorporeal circuit pressure and other factors on extracorporeal circuit lifespan during continuous renal replacement therapy (CRRT). Methods Eightyfive patients with 251 episodes of CRRT and a total of 10,322.2h were recruited in the intensive care unit. We extracted the pressure/minute data of extracorporeal circuit from CRRT machine, treatment parameters, and laboratory data to investigate the effects on extracorporeal circuit lifespan. Results Mild access outflow dysfunction (AOD) event did not affect the circuit lifespan. ModeratEto-severe AOD events had different effects on extracorporeal circuit life using various anticoagulants; moderatEto-severe AOD events significantly shortened the circuit lifespan when no anticoagulant or citrate was used (t=3.179, P=0.002; t=1.949 P=0.054) but had no effect on the circuit lifespan when low molecular weight heparin (LMWH) or heparin was used (t=0.630, P=0.950). Cox analysis suggested that moderatEto-severe AOD event was a risk factor for extracorporeal circuit survival (β=0.638, HR=1.893, 95% CI 1.300～2.756, P=0.001), while citrate (β =- 0.906, HR=0.404, 95% CI 0.304~0.537, P＜0.001) and CVVHDF (β =- 0.722, HR=0.486, 95% CI 0.335～0.704, P＜0.001) were the protective factors. Conclusions Using citrate as the anticoagulant and CVVHDF can prolong the lifespan of CRRT. Clinically, when moderatEto-severe AOD event occurred and citrate or no anticoagulant was used, we should adjust access outflow to extend the circuit lifespan rather than the increase of anticoagulant dose.
1.Ronco C, Cruz D, Bellomo R.Continuous renal replacement therapy in critical illness. Contributions to Nephrology, 2007, 156:309-319.
2.Oudemans-Van Straaten H M, Bosman R J , Koopmans M, et al. Citrate anticoagulation for continuous venovenous hemofiltration[J]. Critical Care Medicine, 2009, 37(2):545-552.
3.Schiffl H, Lang S, Fischer R: Daily dialysis and the outcome of acute renal failure. N Engl J Med 2002,346(5):305–310.
4. Citrate versus heparin anticoagulation for continuous renal replacement therapy: an updated meta-analysis of RCTs[J]. Intensive Care Medicine, 2015, 41(12):2098-2110.
5.Liu C, Mao Z, Kang H, et al. Regional citrate versus heparin anticoagulation for continuous renal replacement therapy in critically ill patients: a meta-analysis with trial sequential analysis of randomized controlled trials[J]. Critical Care, 2016, 20(1):144.
6.Ling Z , Ian B , Guijun Z , et al. Automated electronic monitoring of circuit pressures during continuous renal replacement therapy: a technical report[J]. Critical Care & Resuscitation, 2015, 17(1):51-54.
7.王涌, 陈香美, 郭东阳等. 持续高容量血液滤过治疗挤压综合征影响肌红蛋白清除效率的因素分析[J]. 解放军医学杂志, 2009, 34(3):335-336.
8.Hetzel G R , Schmitz M , Wissing H , et al. Regional citrate versus systemic heparin for anticoagulation in critically ill patients on continuous venovenous haemofiltration: a prospective randomized multicentre trial[J]. Nephrology Dialysis Transplantation, 2011, 26(1):232-239.
9.Brain M , Winson E , Roodenburg O , et al. Non anti-coagulant factors associated with filter life in continuous renal replacement therapy (CRRT): a systematic review and meta-analysis[J]. BMC Nephrology, 2017, 18(1):69.
10.Ling Z , Tanaka A , Zhu G , Patterns and Mechanisms of Artificial Kidney Failure during Continuous Renal Replacement Therapy[J]. Blood Purification, 2015, 41(4):254-263.
11.Eknoyan G, Lameire N, Eckardt K, et al. KDIGO Clinical Practice Guideline for Acute Kidney Injury. Kidney international Supplements. 2012,2:1-138.
12.Kim IB, Fealy N, Baldwin I, et al.Premature circuit clotting due to likely mechanical failure during continuous renal replacement therapy. Blood Purif 2010,30(2):79–83.
13.Mandolfo S , Borlandelli S , Ravani P , et al. How to improve dialysis adequacy in patients with vascular access problems[J]. The Journal of Vascular Access, 2006, 7(2):53-59.
14.Morita Y , Johnson R W , Dorn R E , et al. Regional anticoagulation during hemodialysis using citrate[J]. The American Journal of the Medical Sciences, 1961, 242(2):32-43.
15. de Pont, Anne-Cornélie J. M, Oudemans-Van Straaten H M , Roozendaal K J , et al. Nadroparin versus dalteparin anticoagulation in high-volume, continuous venovenous hemofiltration: A double-blind, randomized, crossover study[J]. Critical Care Medicine, 2000, 28(2):421-425.
16.Reeves J H , Cumming A R , Gallagher L , et al. A controlled trial of low-molecular-weight heparin (dalteparin) versus unfractionated heparin as anticoagulant during continuous venovenous hemodialysis with filtration[J]. Critical Care Medicine, 1999, 27(10):2224-2228.
17.Okuno S , Ishimura E , Kohno K , et al. Serum beta2-microglobulin level is a significant predictor of mortality in maintenance haemodialysis patients[J]. Nephrology Dialysis Transplantation, 2009, 24(2):571-577.
18.丁峰,张明,顾勇等. 不同方式连续性肾脏替代疗法对溶质清除率的影响[J]. 复旦学报(医学版) , 2002, 29(4):268-271
19.邬步云, 徐斌, 邹华等. 两种新型连续性肾脏替代治疗模式对溶质清除的影响[J]. 肾脏病与透析肾移植杂志, 2014, 23(5):437-442.
20.Bellomo R,?Cass A,?Cole L, et a1. Intensity of Continuous Renal-Replacement Therapy in Critically Ill Patients. The New England journal of medicine[J]. 2009, 361(17):1627-1638.
21.Lyndon W D , Wille K M , Tolwani A J . Solute clearance in CRRT: prescribed dose versus actual delivered dose[J]. Nephrol Dial Transplant, 2012, 27(3):952-956.
